New Delhi: India should move beyond its role as a global hub for generic medicines and build a pharmaceutical ecosystem driven by innovation that is “feasible and sustainable”, the country’s top drug ...
Following the March 20, 2026 patent expiry of semaglutide, India is witnessing a rapid influx of generic GLP-1 receptor agonists. This shift is reshaping market dynamics, with evolving regulatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results